

Overview

Volition is a multi-national company developing simple, easy to use blood-based cancer tests to accurately diagnose a range of cancers. The tests are based on the science of Nucleosomics which is the practice of identifying and measuring nucleosomes in the bloodstream - an indication that cancer is present.

Volition's goal is to make the tests as common and simple to use, for both patients and doctors, as existing diabetic and cholesterol blood tests. Volition's research and development activities are currently centred in Belgium as the company focuses on bringing its diagnostic products to market first in Europe, then in the US and ultimately, worldwide.

Management Team

Cameron Reynolds MBA

President & Chief Executive Officer

Mike O'Connell

Chief Financial Officer & Treasurer

Jake Micallef PhD MBA

Chief Scientific Officer

Jason Terrell MD

Chief Medical Officer & Head of US Operations

Rod Rootsart LLB

Corporate Secretary

Thomas Bygott

Sales & Marketing Director

Mark Eccleston PhD MBA

Collaborations Manager

Contact Information


VolitionRx Ltd

1489 West Warm Springs Road

Ste 110

Henderson, NV 89014

NYSE American: VNRX



Share Price	\$1.28
Volume	513.68k
Shares Outstanding	63,179,837
Market Cap	\$80.87m
52 Week High	\$2.74
52 Week Low	\$1.22

as of 07/25/2023

Recent News

Friday, June 23, 2023 - 04:10 PM

[VolitionRx Limited Announces Exercise of Over-Allotment Option by Underwriters](#)

Monday, June 05, 2023 - 04:10 PM

[VolitionRx Limited Announces Closing of \\$16.5 Million Underwritten Public Offering of Common Stock](#)

DISCLAIMER

Except for the historical information contained herein, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on Form 10-K and its quarterly reports on Form

10-Q. The Company does not undertake any obligation to update forward-looking statements. All trademarks and brand names are the property of their respective companies.